ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

ClinicalTrials.gov ID: NCT06534983

Public ClinicalTrials.gov record NCT06534983. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 9, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma

Study identification

NCT ID
NCT06534983
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
362 participants

Conditions and interventions

Interventions

  • Autogene Cevumeran Drug
  • Nivolumab Drug
  • Saline Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 8, 2024
Primary completion
Nov 9, 2027
Completion
Nov 9, 2027
Last update posted
Apr 8, 2026

2024 – 2027

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
Highlands Oncology Group. Springdale Arkansas 72762 Recruiting
Kaiser Permanente - Baldwin Park Baldwin Park California 91706 Suspended
City of Hope Cancer Center Duarte California 91010 Suspended
Kaiser Permanente - Los Angeles (N. Vermont) Los Angeles California 90027 Suspended
Kaiser Permanente - Riverside Riverside California 92505 Suspended
University of California San Francisco San Francisco California 94158 Suspended
Yale Cancer Center New Haven Connecticut 06520 Recruiting
Georgetown University Medical Center Lombardi Cancer Center Washington D.C. District of Columbia 20007 Recruiting
Norton Cancer Institute Louisville Kentucky 40207 Recruiting
Henry Ford Health System Detroit Michigan 48202 Recruiting
Memorial Sloan Kettering Cancer Center Basking Ridge Basking Ridge New Jersey 07920 Recruiting
MSK Monmouth Middletown New Jersey 07748 Recruiting
MSK Bergen Montvale New Jersey 07645 Recruiting
MSK Commack Commack New York 11725 Recruiting
MSK Westchester Harrison New York 10604 Recruiting
Columbia University Irving Medical Center New York New York 10032 Suspended
Memorial Sloan Kettering Cancer Center New York New York 10065 Recruiting
MSK Nassau Uniondale New York 11553 Recruiting
Providence Portland Medical Ctr Portland Oregon 97225 Suspended
AHN Cancer Institute ? Allegheny General Hospital Pittsburgh Pennsylvania 15212 Recruiting
Rhode Island Hospital Providence Rhode Island 02903 Suspended
Bon Secours - St. Francis Hospital Greenville South Carolina 29607 Recruiting
MD Anderson Cancer Center Houston Texas 77030 Recruiting
Inova Schar Cancer Institute Fairfax Virginia 22031 Recruiting
Fred Hutchinson Cancer Research Center Seattle Washington 98109 Recruiting
University of Washington Medical Center Seattle Washington 98195 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06534983, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 8, 2026 · Synced May 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06534983 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →